Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016517 · ClinicalTrials.gov registry record
Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis
A clinical trial, sponsored by Tufts Medical Center.
- Not yet
- Registry status
- 18
- Enrollment target
NCT06016517 is a clinical trial that has not yet begun recruiting, run by Tufts Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT06016517 has not yet begun recruiting, sponsored by Tufts Medical Center.
- NOT YET RECRUITING
- Registry status
- 18 participants
- Enrollment target
Study Summary
The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, finding the best treatment order of treatments is often based on physician choice. The main question this study aims to answer are: * What are the effects of different treatments on RA symptoms and condition for each individual patient * What is the effectiveness of different treatments across all patients enrolled in the N-of-1 study Participants will be enrolled and randomized to a sequence of three U.S. Food and Drug Administration (FDA) approved RA medications: 1. etanercept, 2. adalimumab, 3. upadacitinib 4. tocilizumab. Participants will be asked to complete questionnaires about their condition and quality of life fortnightly, monthly and/or quarterly (either in clinic or remotely) and report their level of pain on alternate days (remotely).
Interventions
- DRUG Adalimumab
- DRUG Upadacitinib
- DRUG Tocilizumab
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-05-01 |
| Est. Completion | 2028-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06016517
The ClinicalTrials.gov registry entry for NCT06016517 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT06016517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06016517 about?
NCT06016517 is a clinical study titled "Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis". The goal of this N-of-1 study is to learn about treatment for individual patients who have rheumatoid arthritis (RA,) for which many treatments are available. The treatments are different in how they work, the way they are given, side- effects, and cost. While treatment guidelines are available, fin...
What is the current status of trial NCT06016517?
This trial is currently not yet recruiting. The enrollment target is 18 participants. The study started on 2026-05-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT06016517?
The interventions under investigation include: Adalimumab (DRUG), Upadacitinib (DRUG), Tocilizumab (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT06016517?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.